- Mission [1]
- FDA's strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science
and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities
to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency
preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical
products; establish an effective tabacco regulation, prevention, and control program; and management for organizational excellence
and accountability. The Allergenic Products Advisory Committee supports FDA's mission and strategic action plan by reviewing
and evaluating available data relating to the safety, effectiveness, and adequacy of labeling of marketed and investigational
allergenic biological products or materials that are administered to humans for the diagnosis, prevention or treatment of
allergies and allergic disease. The Committee also considers the quality and relevance of FDA's research program, which provides
scientific support for the regulation of these products. The Committee supports FDA's mission by using science-based risk
management in all of its activities. The Committee recommendations provide the most health promotion and protection at the
least cost for the public. This Committee assists the Agency in ensuring timely, high quality, cost-effective processes for
review of new technologies/pre-market submissions, effective communication and working relationships with stakeholders to
enhance U.S. and global health outcomes, accurately analyzing risks associated with medical products, facilitating the development
and availability of medical countermeasures to limit the effects of a terrorist attack on the civilian and military populations,
protecting the safety and security of biologics are all key components of FDA's strategic plan objectives.
|
